Studies have shown that CCL2 gene expression is inhibited by 17β-estradiol [58,59], our findings may indicate that this genetic polymorphism, associated with higher levels of CCL2, is most relevant with respect to breast cancer risk against a background of low CCL2 expression. Here, CCL2 is linked to breast carcinoma.